FarFaR - Pharmacy Repository
University of Belgrade, Faculty of Pharmacy
    • English
    • Српски
    • Српски (Serbia)
  • English 
    • English
    • Serbian (Cyrilic)
    • Serbian (Latin)
  • Login
View Item 
  •   FarFaR
  • Pharmacy
  • Radovi istraživača / Researchers’ publications
  • View Item
  •   FarFaR
  • Pharmacy
  • Radovi istraživača / Researchers’ publications
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Dyslipidemia in type 2 diabetes mellitus

Dislipidemija u dijabetes melitusu tip 2

Thumbnail
2019
Dyslipidemia_in_type_pub_2019.pdf (240.1Kb)
Authors
Stefanović, Aleksandra
Zeljković, Aleksandra
Vekić, Jelena
Spasojević-Kalimanovska, Vesna
Jelić-Ivanović, Zorana
Spasić, Slavica
Article (Published version)
Metadata
Show full item record
Abstract
Type 2 diabetes mellitus is a chronic high-prevalence metabolic disease, which is characterized by hyperglycaemia, but also with lipid and protein metabolism disorders. Patients with type 2 diabetes have a high risk for cardiovascular disease (CVD) development and dyslipidemia is considered as a key marker of this increased risk. Hypertriglyceridemia, reduced high density lipoprotein cholesterol (HDL-c) concentrations, and a shift in low-density lipoprotein particles (LDL) distribution toward the small, triglycerides-rich particles, are the most important changes in the lipid profile in diabetes.Type 2 diabetes is a metabolic disorder associated with low grade inflammation and oxidative stress, so in this condition high density lipoprotein particles (HDL) also undergo structural and functional changes and, as a consequence, lose their atheroprotective role. Dyslipidemia treatment in type 2 diabetes patients younger than 40 and with...out any other risk factor for CVD development starts with changes in a lifestyle, but in patients older than 40 years, first line medications are statins.Glycemic and lipid control in type 2 diabetes patients significantly reduces CVD risk.

Dijabetes melitus tip 2 je hronično oboljenje sa visokom prevalencom, koje se karakteriše hiperglikemijom, ali i poremećajima u metabolizmu lipida i proteina. Pacijenti sa tipom 2 dijabetesa imaju visok rizik za razvoj kardiovaskularnih bolesti (KVB) i upravo se dislipidemija smatra ključnim uzročnikom ovog povećanog rizika. Hipertrigliceridemija, snižena koncentracija holesterola u lipoproteinskim česticama visoke gustine (HDL-h) i promena u raspodeli lipoproteinskih čestica niske gustine (LDL) u smeru većeg udela malih čestica, bogatih trigliceridima, predstavljaju najvažnije promene lipidnog profila koje se odnose na dislipidemiju u dijabetesu. Kako je dijabetes stanje kontinuirane blage inflamacije niskog stepena i stalne produkcije slobodnih radikala, HDL lipoproteinske čestice takođe podležu strukturnim i funkcionalnim promenama, usled čega gube svoje ateroprotektivne osobine. Terapija dislipidemije kod... pacijenata mlađih od 40 godina bez prisutnih drugih faktora rizika za razvoj KVB počinje promenom životnog stila, a kod pacijenata starijih od 40 godina lekovi izbora u terapiji su statini. Glikemijska i lipidna kontrola kod pacijenata sa tipom 2 dijabetesa značajno umanjuje rizik od nastanka KVB.

Keywords:
Cardiovascular disease risk / Diabetes mellitus type 2 / Dyslipidemia / dijabetes melitus tip 2 / dislipidemija / zik za razvoj kardiovaskularnih bolesti
Source:
Arhiv za farmaciju, 2019, 69, 5, 338-348
Publisher:
  • Beograd : Savez farmaceutskih udruženja Srbije
Projects:
  • Interactive role of dyslipidemia, oxidative stress and inflammation in atherosclerosis and other diseases: genetic and biochemical markers (RS-175035)

DOI: 10.5937/arhfarm1905338S

ISSN: 0004-1963

Scopus: 2-s2.0-85080854356
[ Google Scholar ]
URI
http://farfar.pharmacy.bg.ac.rs/handle/123456789/3560
Collections
  • Radovi istraživača / Researchers’ publications
Institution
Pharmacy
TY  - JOUR
AU  - Stefanović, Aleksandra
AU  - Zeljković, Aleksandra
AU  - Vekić, Jelena
AU  - Spasojević-Kalimanovska, Vesna
AU  - Jelić-Ivanović, Zorana
AU  - Spasić, Slavica
PY  - 2019
UR  - http://farfar.pharmacy.bg.ac.rs/handle/123456789/3560
AB  - Type  2  diabetes  mellitus  is  a  chronic  high-prevalence  metabolic  disease,  which  is characterized by hyperglycaemia, but also with lipid and protein metabolism disorders. Patients with  type  2  diabetes  have  a  high  risk  for  cardiovascular  disease  (CVD)  development  and dyslipidemia is considered as a key marker of this increased risk. Hypertriglyceridemia, reduced high  density  lipoprotein  cholesterol  (HDL-c)  concentrations,  and  a  shift  in  low-density lipoprotein  particles  (LDL)  distribution  toward  the  small,  triglycerides-rich  particles,  are  the most important changes in the lipid profile in diabetes.Type 2 diabetes is a metabolic disorder associated with low grade inflammation and oxidative stress, so in this condition high density lipoprotein  particles  (HDL)  also  undergo  structural  and  functional  changes  and,  as  a consequence, lose their atheroprotective role. Dyslipidemia treatment in type 2 diabetes patients younger than 40 and without any other risk factor for CVD development starts with changes in a lifestyle, but in patients older than 40 years, first line medications are statins.Glycemic and lipid control in type 2 diabetes patients significantly reduces CVD risk.
AB  - Dijabetes melitus tip 2 je hronično oboljenje sa visokom prevalencom, koje se karakteriše hiperglikemijom,  ali  i  poremećajima  u  metabolizmu  lipida  i  proteina.  Pacijenti  sa  tipom  2 dijabetesa imaju visok rizik za razvoj kardiovaskularnih bolesti (KVB) i upravo se dislipidemija smatra  ključnim  uzročnikom  ovog  povećanog  rizika.  Hipertrigliceridemija,  snižena koncentracija  holesterola  u  lipoproteinskim  česticama  visoke  gustine  (HDL-h)  i  promena  u raspodeli  lipoproteinskih  čestica  niske  gustine  (LDL)  u  smeru  većeg  udela  malih  čestica, bogatih  trigliceridima,  predstavljaju  najvažnije  promene  lipidnog  profila  koje  se  odnose  na dislipidemiju  u  dijabetesu.  Kako je  dijabetes  stanje  kontinuirane  blage  inflamacije  niskog stepena  i  stalne  produkcije  slobodnih  radikala,  HDL  lipoproteinske  čestice  takođe  podležu strukturnim  i  funkcionalnim  promenama,  usled  čega  gube  svoje  ateroprotektivne  osobine. Terapija dislipidemije kod pacijenata mlađih od 40 godina bez prisutnih drugih faktora rizika za razvoj KVB počinje promenom životnog stila, a kod pacijenata starijih od 40 godina lekovi izbora u terapiji su statini. Glikemijska i lipidna kontrola kod pacijenata sa tipom 2 dijabetesa značajno umanjuje rizik od nastanka KVB.
PB  - Beograd : Savez farmaceutskih udruženja Srbije
T2  - Arhiv za farmaciju
T1  - Dyslipidemia in type 2 diabetes mellitus
T1  - Dislipidemija u dijabetes melitusu tip 2
VL  - 69
IS  - 5
SP  - 338
EP  - 348
DO  - 10.5937/arhfarm1905338S
ER  - 
@article{
author = "Stefanović, Aleksandra and Zeljković, Aleksandra and Vekić, Jelena and Spasojević-Kalimanovska, Vesna and Jelić-Ivanović, Zorana and Spasić, Slavica",
year = "2019",
url = "http://farfar.pharmacy.bg.ac.rs/handle/123456789/3560",
abstract = "Type  2  diabetes  mellitus  is  a  chronic  high-prevalence  metabolic  disease,  which  is characterized by hyperglycaemia, but also with lipid and protein metabolism disorders. Patients with  type  2  diabetes  have  a  high  risk  for  cardiovascular  disease  (CVD)  development  and dyslipidemia is considered as a key marker of this increased risk. Hypertriglyceridemia, reduced high  density  lipoprotein  cholesterol  (HDL-c)  concentrations,  and  a  shift  in  low-density lipoprotein  particles  (LDL)  distribution  toward  the  small,  triglycerides-rich  particles,  are  the most important changes in the lipid profile in diabetes.Type 2 diabetes is a metabolic disorder associated with low grade inflammation and oxidative stress, so in this condition high density lipoprotein  particles  (HDL)  also  undergo  structural  and  functional  changes  and,  as  a consequence, lose their atheroprotective role. Dyslipidemia treatment in type 2 diabetes patients younger than 40 and without any other risk factor for CVD development starts with changes in a lifestyle, but in patients older than 40 years, first line medications are statins.Glycemic and lipid control in type 2 diabetes patients significantly reduces CVD risk., Dijabetes melitus tip 2 je hronično oboljenje sa visokom prevalencom, koje se karakteriše hiperglikemijom,  ali  i  poremećajima  u  metabolizmu  lipida  i  proteina.  Pacijenti  sa  tipom  2 dijabetesa imaju visok rizik za razvoj kardiovaskularnih bolesti (KVB) i upravo se dislipidemija smatra  ključnim  uzročnikom  ovog  povećanog  rizika.  Hipertrigliceridemija,  snižena koncentracija  holesterola  u  lipoproteinskim  česticama  visoke  gustine  (HDL-h)  i  promena  u raspodeli  lipoproteinskih  čestica  niske  gustine  (LDL)  u  smeru  većeg  udela  malih  čestica, bogatih  trigliceridima,  predstavljaju  najvažnije  promene  lipidnog  profila  koje  se  odnose  na dislipidemiju  u  dijabetesu.  Kako je  dijabetes  stanje  kontinuirane  blage  inflamacije  niskog stepena  i  stalne  produkcije  slobodnih  radikala,  HDL  lipoproteinske  čestice  takođe  podležu strukturnim  i  funkcionalnim  promenama,  usled  čega  gube  svoje  ateroprotektivne  osobine. Terapija dislipidemije kod pacijenata mlađih od 40 godina bez prisutnih drugih faktora rizika za razvoj KVB počinje promenom životnog stila, a kod pacijenata starijih od 40 godina lekovi izbora u terapiji su statini. Glikemijska i lipidna kontrola kod pacijenata sa tipom 2 dijabetesa značajno umanjuje rizik od nastanka KVB.",
publisher = "Beograd : Savez farmaceutskih udruženja Srbije",
journal = "Arhiv za farmaciju",
title = "Dyslipidemia in type 2 diabetes mellitus, Dislipidemija u dijabetes melitusu tip 2",
volume = "69",
number = "5",
pages = "338-348",
doi = "10.5937/arhfarm1905338S"
}
Stefanović A, Zeljković A, Vekić J, Spasojević-Kalimanovska V, Jelić-Ivanović Z, Spasić S. Dislipidemija u dijabetes melitusu tip 2. Arhiv za farmaciju. 2019;69(5):338-348
Stefanović, A., Zeljković, A., Vekić, J., Spasojević-Kalimanovska, V., Jelić-Ivanović, Z.,& Spasić, S. (2019). Dislipidemija u dijabetes melitusu tip 2.
Arhiv za farmacijuBeograd : Savez farmaceutskih udruženja Srbije., 69(5), 338-348.
https://doi.org/10.5937/arhfarm1905338S
Stefanović Aleksandra, Zeljković Aleksandra, Vekić Jelena, Spasojević-Kalimanovska Vesna, Jelić-Ivanović Zorana, Spasić Slavica, "Dislipidemija u dijabetes melitusu tip 2" 69, no. 5 (2019):338-348,
https://doi.org/10.5937/arhfarm1905338S .

DSpace software copyright © 2002-2015  DuraSpace
About FarFaR - Pharmacy Repository | Send Feedback

OpenAIRERCUB
 

 

All of DSpaceInstitutionsAuthorsTitlesSubjectsThis institutionAuthorsTitlesSubjects

Statistics

View Usage Statistics

DSpace software copyright © 2002-2015  DuraSpace
About FarFaR - Pharmacy Repository | Send Feedback

OpenAIRERCUB